Hear from the Experts

Search for a New Molecule: Shift from Generics to Novel Drugs

Supported by

Powered by

Our Speakers

Sai Prasad
Executive Director, Bharat Biotech

Dr Anand Anandkumar
Co-Founder & Chief Executive Officer, Bugworks Research

Dr Vinod Kotwal
Member Secretary, National Pharmaceutical Pricing Authority

Dr Parul Ganju
Co-founder and CEO, Ahammune Biosciences

Saurabh Singal
Founder, KnowDis/ Molecule AI

Moderator

Dr Satya Dash
Founding Head Strategy-BIRAC, Founding CEO-BITS BioCyTiH Foundation

The Indian pharmaceutical industry has long been recognised as a global leader in the production of generic drugs, which has helped to bring affordable healthcare to millions of people around the world. However, with the increasing demand for more effective and personalised therapies, there is a need for the industry to shift its focus from generics to novel drugs. In this round table discussion with a panel of industry experts, we aim to explore the challenges and opportunities that come with this shift, and to identify strategies for accelerating the discovery and development of new molecules in the Indian pharmaceutical industry.

BioSpectrum India Excellence
Awards 2023

For more details, contact:
Apoorva Mahajan
Project Lead
apoorva.mahajan@mmactiv.com


Dr. Manbeena Chawla
Executive Editor
manbeena.chawla@mmactiv.com


Vrushti Kothari
Media Relationship Executive
vrushti.kothari@mmactiv.com

© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer

Web Interface Conceived and Powered By : SCI Knowledge Interlinks